MDM2 and Miyoshi myopathy: In canine MM, these recurrent amplifications target well-recognized oncogenes, such as CDK4, which are involved in the early phase of the cell cycle, and MDM2, whose protein inhibits p53, as well as several candidate oncogenes localized on CFA 30 amplifications, which remain unidentified in human MM.